In contrast, HER2-positive BC is directly linked to ERBB2 amplification, which is the basis for the effectiveness of conventional anti-HER2 agents in treating these tumors.[3] Differences between these 2 subtypes can be observed at the clinicopathological and molecular levels, with visible macroscopic distinctions on DCE-MRI and subtle detectable variations in high-throughput radiomic signatures. Here, ERBB2 is linked to breast cancer.